Breaking News: Molecular Templates Receives Notification of Deficiency from Nasdaq Due to Delayed Quarterly Report Filing and Bid Price Failure
A Closer Look at Molecular Templates, Inc.’s Recent Nasdaq Listing Rule Violation AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel…